|  |
NG2 (%)
|
PDGFRα (%)
|
CD11b (%)
|
PDGFRβ (%)
|
---|
Sham
|
WT
| 6.12 ± 1.7c
| 8.32 ± 2.1c
| - | 6.62 ± 0.9c
|
 |
KO
| - | 6.77 ± 2.6c
| - | 4.82 ± 1.4c
|
1W
|
WT
| 100 ± 8.2 | 100 ± 11.5 | 100 ± 9.1 | 100 ± 17.7 |
 |
KO
| - | 72.69 ± 16.8* | 33.23 ± 10.3*** | 60.59 ± 15* |
2W
|
WT
| 75.45 ± 6b
| 111.4 ± 1.9 | 174.83 ± 18.6c
| 121.71 ± 18.7 |
 |
KO
| - | 89.7 ± 6.6*** | 103.13 ± 16.6c** | 87.71 ± 12.4a* |
6W
|
WT
| 23.99 ± 11.7c
| 33.01 ± 4.9c
| 6.41 ± 0.8c
| 33.83 ± 2.6c
|
 |
KO
| - | 40.8 ± 6.4a
| 4.21 ± 1.3c* | 44.69 ± 7* |
- The abundance of various cell types (NG2+, PDGFRα+, CD11b+, PDGFRβ+) in demyelinated lesions from 1-6 weeks post-lysolecithin injection is illustrated by normalizing cell density values to cell densities found in wild type mice at 1 week post-surgery (these 1 week values are designated as 100%). Values represent means ± S.D. Statistically significant differences are indicated by * < 0.05; ** < 0.01; *** < 0.001 when values were compared between WT and NG2 null mice at the same post-injection week. a < 0.05; b < 0.01; c < 0.001 represent statistically significant differences between values obtained for mice of the same genotype when compared to the 1st week post-injection.